We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis.
- Authors
Liu, Yunqing; Yan, Dejun; Yang, Lin; Chen, Xian; Hu, Chun; Chen, Meilan
- Abstract
This article discusses the potential of Stathmin 2 (STMN2) as a treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis (ALS). TDP-43 is a protein associated with ALS, and its abnormal modifications lead to neurotoxic effects. The study found that the expression of STMN2 was significantly reduced in the presence of TDP-43 depletion, and restoring STMN2 levels rescued neurite outgrowth and axon regeneration. The article suggests that STMN2 is involved in ALS pathology and could be a promising therapeutic approach. However, further research and in vivo examination are needed to confirm the efficacy and safety of targeting STMN2.
- Subjects
AMYOTROPHIC lateral sclerosis; AFFERENT pathways; RILUZOLE; COAT proteins (Viruses); DNA-binding proteins; HUMAN embryonic stem cells; POSTMORTEM changes; INTRONS; DORSAL root ganglia
- Publication
Translational Neurodegeneration, 2024, Vol 13, Issue 1, p1
- ISSN
2047-9158
- Publication type
Article
- DOI
10.1186/s40035-024-00413-0